Regulation of Factor VIII Expression and Activity by von Willebrand Factor

Introduction

Hemostasis requires a cascade of proteolytic reactions that occurs on the surfaces of damaged or activated cells, such as platelets, white blood cells, and endothelial cells. Initial damage to a blood vessel results in platelet adhesion to the subendothelium mediated by von Willebrand factor (vWF). Subsequently, platelet activation and aggregation occur. Protease complexes assemble on the surface of activated cells and are converted sequentially to their proteolytically active forms to result in a localized burst of thrombin generation and the conversion of soluble fibrinogen to insoluble fibrin. Activation of the extrinsic coagulation pathway occurs to form a factor VIIa—tissue factor complex on activated or damaged endothelial cells. In turn, factor VIIa activates the intrinsic pathway of blood coagulation by activating factor IXa, which in turn interacts with activated factor VIIIa, in the presence of calcium and negatively-charged phospholipids, to convert factor X to factor Xa. Factor Xa then acts with its cofactor factor Va, in the presence of calcium and negatively-charged phospholipids, to convert prothrombin to thrombin. Initial factor Xa and thrombin generation feeds back to activate cofactors VIII and V. Activation of these cofactors in the intrinsic pathway serves to amplify thrombin generation. The importance of this cascade in hemostasis is evident from the characterization of individuals who are defective in proteins that function in this cascade. The most common of these disorders, a deficiency of factor VIII that results in hemophilia A, was documented more than 1,700 years ago in the Talmud.¹

The genetics of hemophilia A was described in the early 1800s, and transfusion of whole blood was shown to successfully treat a hemophilia A-associated bleeding episode by 1840.^2,3 Although the presence of factor VIII in plasma was demonstrated in 1911⁴ and its role in hemostasis was described in 1937,⁵ a detailed biochemical and structural characterization of factor VIII was achieved only within the last 20 years. Prior to 1980, the relationship between hemophilia A and von Willebrand’s disease generated a great deal of confusion because the autosomally-inherited von Willebrand’s disease is associated with some degree of factor VIII deficiency, although hemophilia is an X-linked disease. In addition, early preparations of antihemophilia factor not only corrected the clotting time of hemophilic plasma, but also restored platelet adhesion and aggregation defects in the plasma of patients with von Willebrand’s disease. It is now appreciated that factor VIII and vWF are two separate proteins that exist as a complex in plasma. They are under separate genetic control, have distinct biochemical and immunological properties, and have unique and essential physiological functions (Table 1). Factor VIII is the X-linked gene product that accelerates the factor IXa-mediated activation of factor X by four orders of magnitude. vWF is an autosomal gene product that is essential for platelet adhesion to the subendothelium and for ristocetin-induced platelet aggregation. In addition, vWF plays a critical role in the regulation of factor VIII activity by 1) stabilizing factor VIII on secretion from the cell;^6,7 2) requiring the survival of factor VIII in plasma,^8,9 3) protecting factor VIII from activation by factor Xa and inactivation by activated protein C;^10,11 and 4) preventing factor VIII from binding to phospholipids and activated platelets.^3,12

It is likely that vWF mediates its inhibitory properties on factor VIII by preventing factor VIII from binding to phospholipids, an interaction required for both factor Xa- and APC-mediated cleavage of factor VIII. Because vWF and factor VIII are found in plasma as a complex and vWF stabilizes factor VIII and regulates its activity, the activities of these two proteins are intimately intertwined.

• References

• 1 Rosner F. Hemophilia in the Talmud and rabbinic writings. Ann Intern Med. 1969; 70: 833-837.
• 2 Otto JE. An account of an hemorrhagic disposition existing in certain families. Med Repository. 1803; 6: 1.
• 3 Lane S. Haemorrhagid diathesis. Successful transfusion of blood. Lancet. 1840; 1: 185-188.
• 4 Addis T. The pathogenesis of hereditary hemophilia. J Pathol Bacteriol. 1911; 15: 427-452.
• 5 Patek AJ, Taylor FHL. Hemophilia II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood. J Clin Invest. 1937; 16: 113-124.
• 6 Kaufman RJ, Wasley LC, Dorner AJ. Synthesis processing and secretion of factor VIII expressed in mammalian cells. J Biol Chem. 1988; 263: 6352-6362.
• 7 Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimerization and propeptide cleavage in the binding and stabilization of factor VIII. J Biol Chem. 1991; 266: 21948-21955.
• 8 Over J, Sixma JJ, Bruine MH, Trieschnigg MC, Vlooswijk RA, Beeser-Visser NH, Bouma BN. Survival of 125 iodine-labeled factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human factor VIII. J Clin Invest. 1978; 62: 223-234.
• 9 Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest. 1977; 60: 390-404.
• 10 Koedam JA, Hamer RJ, Beeser-Visser NH, Bouma BN, Sixma JJ. The effect of von Willebrand factor on activation of factor VIII by factor Xa. Eur J Biochem. 1990; 189: 229-234.
• 11 Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest. 1988; 82: 1236-1243.
• 12 Nesheim M, Pittman DD, Giles AR, Fass DN, Wang JH, Slonosky D, Kaufman RJ. The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem. 1991; 266: 17815-17820.
• 13 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998; 67: 395-424.
• 14 Bonthran DT, Handin RI, Kaufman RJ, Wasley LC, Orr LD, Mitsock LM, Ewenstein B, Loscalzo J, Ginsberg D, Orkin SH. Pre-pro-von Willebrand factor: Structure and expression in heterologous cells. Nature 1986; 324: 270-273.
• 15 Hoyer LW, Shainoff JR. Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers. Blood 1980; 55: 1056-1059.
• 16 Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140-1143.
• 17 Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol. 1984; 99: 2123-2130.
• 18 Sadler JE. von Willebrand factor. J Biol Chem. 1991; 266: 22777-22780.
• 19 Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino terminal 272 amino acid residues of von Willebrand factor. J Biol Chem. 1987; 262: 8443-8446.
• 20 Takahashi Y, Kalafatis M, Girma JP, Sewerin K, Andersson LO, Meyer D. Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor. Blood 1987; 70: 1679-1682.
• 21 Mazurier C. von Willebrand disease masquerading as haemophilia A. Thromb Haemost. 1992; 67: 391-396.
• 22 Mazurier C, Meyer D. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease—results of an international survey. Thromb Haemost. 1996; 76: 270-274.
• 23 Jorieux S, Gaucher C, Goudemand J, Mazurier C. A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization. Blood 1998; 92: 4663-4670.
• 24 Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347.
• 25 Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL, Delwart E, Tuddenham EGD, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNA cloned. Nature 1984; 312: 330-337.
• 26 Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-342.
• 27 Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA. 1987; 84: 4846-4850.
• 28 Koschinsky ML, Funk WD, von Ooar BA, Macgillivray RTA. Complete cDNA sequence of human preceruloplasmin. Proc Natl Acad Sci USA. 1986; 83: 5086-5090.
• 29 Tagliavacca L, Moon N, Dunham WR, Kaufman RJ. Identification and functional requirement of Cu(II) and its ligands within coagulation factor VIII. J Biol Chem. 1997; 272: 27428-27434.
• 30 Stubbs JD, Lekutis C, Singer KL, Bui A, Yuzuki D, Srinivasan U, Parry G. cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences. Proc Natl Acad Sci USA. 1990; 87: 8417-8421.
• 31 Pittman DD, Wang JH, Kaufman RJ. Identification and functional importance of tyrosine-sulfate residues within recombinant factor VIII. Biochemistry. 1992; 31: 3315-3323.
• 32 Michnick DA, Pittman DD, Kaufman RJ. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem. 1994; 269: 20095-20102.
• 33 Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem. 1997; 272: 18007-18014.
• 34 Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA. 1997; 94: 11851-11856.
• 35 Journet AM, Saffaripour S, Cramer EM, Tenza D, Wagner DD. von Willebrand factor storage requires intact prosequence cleavage site. Eur J Cell Biol. 1993; 60: 31-41.
• 36 Hop C, Fontijn R, van Mourik JA, Pannekoek H. Polarity of constitutive and regulated von Willebrand factor secretion by transfected MDCK-II cells. Exp Cell Res. 1997; 230: 352-361.
• 37 Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek H. Biogenesis of von Willebrand factor-containing organelles in heterologous transfected CV-1 cells. EMBO J. 1993; 12: 749-758.
• 38 Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood 1994; 83: 3536-3544.
• 39 Wise B, Pittman D, Handin R, Kaufman RJ, Orkin SH. The propeptide of vWF is required for the assembly of von Willebrand subunits into disulfide-linked multimers cell. Cell. 1988; 52: 229-236.
• 40 Verweij CL, Hart M, Pannekoek H. Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation. EMBO J. 1987; 6: 2885-2890.
• 41 Wise RJ, Barr PJ, Wong PA, Kiefer MC, Brake AJ, Kaufman RJ. Expression of human proprotein processing enzyme: Correct cleavage of the von Willebrand factor precursor at a paired basic amino acid site. Proc Natl Acad Sci USA. 1990; 87: 9378-9382.
• 42 van de Ven WJ, Voorberg J, Fontijn R, Pannekoek H, van den Ouweland AM, van Duijnhoven HL, Roebroek AJ, Siezen RJ. Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes. Mol Biol Rep. 1990; 14: 265-275.
• 43 Wion KL, Kelly D, Summerfield JA, Tuddenham EGD, Lawn RM. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317: 726-729.
• 44 Lewis JH, Bontempo FA, Spero JA, Ragni MV, Starzl TE. Liver transplantation in a hemophiliac. N Engl J Med. 1985; 312: 1189-1190.
• 45 Bontempo FA, Lewis JH, Gorec TJ, Spero JA, Ragni MV, Scott JP, Starzl TE. Liver transplantation in hemophilia A. Blood 1987; 69: 1721-1724.
• 46 Kelly DA, Summerfield JA, Tuddenham EG. Localization of factor VIIIC: antigen in guinea-pig tissues and isolated liver cell fractions. Br J Haematol. 1984; 56: 535-543.
• 47 Zelechowska MG, van Mourik JA, Brodniewicz-Proba T. Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature 1985; 317: 729-730.
• 48 Riezman H, Munn A, Geli MI, Hicke L. Actin-, myosin- and ubiquitin-dependent endocytosis. Experientia. 1996; 52: 1033-1041.
• 49 Liu L, Xia S, Seifert J. Transplantation of spleen cells in patients with hemophilia A. A report of 20 cases. Transpl Int. 1994; 7: 201-206.
• 50 Fay PJ. Reconstitution of human factor VIII from isolated subunits. Arch Biochem Biophys. 1988; 252: 525-553.
• 51 Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI. The effect of von Willebrand factor co-expression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol. 1989; 9: 1233-1242.
• 52 Dorner AJ, Bole DG, Kaufman RJ. The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol. 1987; 105: 2665-2674.
• 53 Dorner AJ, Wasley LC, Kaufman RJ. Protein dissociation from GRP78 and secretion is blocked by depletion of cellular ATP levels. Proc Natl Acad Sci USA. 1990; 87: 7429-7432.
• 54 Marquette KA, Pittman DD, Kaufman RJ. A 110 amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells. J Biol Chem. 1995; 270: 10297-10303.
• 55 Swaroop M, Moussalli M, Pipe SW, Kaufman RJ. Mutagenesis of a potential BiP binding site enhances secretion of coagulation factor VIII. J Biol Chem. 1997; 272: 24121-24124.
• 56 Vlot AJ. Factor VIII and von Willebrand factor. Thromb Haemost. 1998; 79: 456-465.
• 57 Vlot AJ, Koppelman SJ, Meijers JC, Dama C, van den Berg HM, Bouma BN, Sixma JJ, Willems GM. Kinetics of factor VIII-von Willebrand factor association. Blood 1996; 87: 1809-1816.
• 58 Lollar P, Parker CG. Stoichiometry of the porcine factor VIII-von Willebrand factor association. J Biol Chem. 1987; 262: 17572-17576.
• 59 Zucker MB, Soberano ME, Johnson AJ, Fulton AJ, Kowalski S, Adler M. The in vitro association of antihemophilic factor and von Willebrand factor. Thromb Haemost. 1983; 49: 37-41.
• 60 Hamer RJ, Koedam JA, Beeser-Visser NH, Bertina RM, van Mourik JA, Sixma JJ. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. Eur J Biochem. 1987; 166: 37-43.
• 61 Leyte A, Verbeet MP, Brodniewicz-Proba T, van Mourik JA, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII. Biochem J. 1989; 257: 679-683.
• 62 Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995; 85: 3150-3157.
• 63 Tuddenham EGD, Lane RS, Rotblat F, Johnson AJ, Snape TJ, Middleton S, Kernoff PB. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human hemophilia A and von Willebrand’s disease. Br J Haematol. 1982; 52: 259-267.
• 64 Bendetowicz AV. Binding FVIII to vWF is enabled by cleavage of the vWF propeptide and enhanced by formation of disulfide-linked multimers. Blood 1998; 92: 529-538.
• 65 Kosik KS, Furie B. Thrombotic stroke associated with elevated plasma factor VIII. Ann Neurol. 1980; 8: 435-437.
• 66 Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis [see comments]. Lancet. 1995; 345: 152-155.
• 67 Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79: 3130-3137.
• 68 Kaufman RJ, Dorner AJ, Fass DN. von Willebrand factor elevates plasma factor VIII without induction of factor VIII messenger RNA in the liver. Blood 1999; 93: 193-197.
• 69 Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders [see comments]. Blood 1988; 72: 1449-1455.
• 70 Menache D, Aronson DL, Darr F, Montgomery RR, Gill JC, Kessler CM, Lusher JM, Phatak PD, Shapiro AD, Thompson AR, White GC. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Br J Haematol. 1996; 94: 740-745.
• 71 Rosenberg JB, Foster PA, Kaufman RJ, Vokac EA, Moussalli M, Kroner PA, Montgomery RR. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest. 1997; 101: 613-624.
• 72 Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986; 25: 505-512.
• 73 Hill-Eubanks DC, Parker CG, Lollar P. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. Proc Natl Acad Sci USA. 1989; 86: 6508-6512.
• 74 Regan LM, Fay PJ. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem. 1995; 270: 8546-8552.
• 75 Pittman DD, Kaufman RJ. The proteolytic requirements for activation and inactivation of antihemophilic factor (factor VIII). Proc Natl Acad Sci USA. 1988; 85: 2429-2433.
• 76 Lollar P, Parker CG. Subunit structure of thrombin-activated porcine factor VIII. Biochemistry. 1987; 28: 666-674.
• 77 Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem. 1991; 266: 8957-8962.
• 78 Pittman DD, Millenssen M, Bauer K, Kaufman RJ, Marquette K. The A2 domain of human recombinant derived factor VIII is required for procoagulant activity but not for thrombin cleavage. Blood 1992; 79: 389-397.
• 79 Pittman DD, Alderman EA, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain deleted factor VIII. Blood 1993; 81: 2925-2935.
• 80 Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost. 1997; 78: 256-260.
• 81 Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated protein C and its analogy with factor V. Blood 1984; 63: 486-489.
• 82 Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem. 1991; 266: 20139-20145.
• 83 Amano K, Michnick DA, Moussalli M, Kaufman RJ. Mutation at either Arg336 or Arg562 in Factor VIII is insufficient for complete resistance to activated protein C (APC)-mediated inactivation: Implications for the APC resistance test. Thromb Haemost. 1998; 79: 557-563.
• 84 Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem. 1990; 265: 1688-1692.
• 85 Fay PJ, Smudzin TM. Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor VIIIa. J Biol Chem. 1992; 267: 13246-13250.
• 86 Lollar P, Parker CG. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem. 1991; 265: 12481-12486.
• 87 Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem. 1996; 271: 27424-27431.
• 88 Saenko EL, Scandella D, Yakhyaev AV, Greco NJ. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets. J Biol Chem. 1998; 273: 27918-27926.